This RSS feed URL is deprecated, please update. New URLs can be found in the footers at (blog)

Belgian Antibody Proves Effective to Treat Myasthenia Gravis (blog)
A Phase II proof of concept study has shown that one of Argenx' antibodies is effective in treating the neuromuscular disease myasthenia gravis. Argenx has released the results from a Phase II trial with ARGX-113 (efgartigimod), in which the antibody ...
argenx SE (ARGX) PT Raised to $64 at Wedbush on 'Myasthenia Gravis Data Impressive'
ArgenX reports hints to efficacy of ARGX-113 in generalised myasthenia gravisEuropean Biotechnology
argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in ...GlobeNewswire (press release)
Nasdaq -Seeking Alpha
all 9 news articles »


Myasthenia Gravis Market By Treatment Methodology Analysis 2017 To 2022
Global Myasthenia Gravis Market: Size, Trends & Forecasts (2017-2021), provides a detailed analysis of the myasthenia gravis market with description of market size and growth. The analysis includes market size in terms of value, and market share on the ...
Myasthenia Gravis Drugs Global Market Attractiveness, Competitive Landscape and Key Players Pfizer, Shire, Flamel ...Newsient (blog)
Global Myasthenia Gravis Drugs Market 2021 Growth, Drivers, Trends, Demand, Share, Opportunities and AnalysissatPRnews (press release)
Myasthenia Gravis Drugs Market Pharmaceuticals Analysis 2017Equity Insider (press release)
First News Service
all 13 news articles »

Myasthenia Gravis News

ARGX-113, an Investigational Therapy for Myasthenia Gravis, Shows Promise in Phase 2 Trial
Myasthenia Gravis News
“These results strengthen our conviction that reducing pathogenic autoantibodies may offer an innovative approach to treat myasthenia gravis and could give rise to potential therapeutic benefits in other neuromuscular conditions that are similarly ...

Global Myasthenia Gravis Market: Segmental Highlights and Table ...
Digital Journal
Albany, NY -- (SBWIRE) -- 12/15/2017 -- According to a research report by Transparency Market Research (TMR), the global myasthenia gravis market is anticipated to be worth US$2,313.1 mn by the end of 2025 from a valuation of US$975.1 mn in 2016 ...

and more »

Neurology Advisor

Myasthenia Gravis Impairment Index Indicates Response to Prednisone, IVIg, PLEX
Neurology Advisor
Ocular scores were more responsive to prednisone than intravenous immunoglobulin/plasma exchange, but the baseline ocular scores were higher in the prednisone group; however, scores were significant. The Myasthenia Gravis Impairment Index (MGII) is a ...

Otaku Reports

Global Myasthenia Gravis Market Applications(Various Sectors), Trending Demands, Economy & Forecast 2022
NB Herard
Brooklyn, NY — 12/14/2017 — Qyresearchreports include new market research report Global Myasthenia Gravis Market Size, Status and Forecast 2022 to its huge collection of research reports. A new report has been added to the expansive database of ...
Myasthenia Gravis Market Analysis, Growth Forecast Analysis by ...MilTech

all 3 news articles »

Neurology Advisor

Eculizumab Safe, Tolerable for Refractory Generalized Myasthenia Gravis
Neurology Advisor
Eculizumab is safe, tolerable, and produces similar effects to placebo on activities of daily living for patients with anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis, according to results from a phase 3, double ...

The Assistance Fund Opens Copay Program for Individuals with ...
Business Wire (press release)
The Assistance Fund is now providing financial support for insurance, deductibles, copays and medical expenses for individuals with myasthenia gravis.

and more »

Low-Dose Oral Corticosteroids Offer More Promising Outcomes for MG Patients than Higher Doses
Myasthenia Gravis News
Researchers found that a low-dose regimen of oral corticosteroids is better than high- or intermediate-dose regimens in maintaining treatment goals for patients with myasthenia gravis (MG). The study “Oral corticosteroid dosing regimen and long-term ...

Phase 1 Trial of GTP-004 Initiated as Therapy for Myasthenia Gravis Treatment Side Effects
Myasthenia Gravis News
GT Biopharma has launched a proof-of-concept Phase 1 trial of its investigational therapy GTP-004 for the treatment of myasthenia gravis. The trial's primary goal is to demonstrate the therapy improves the gastrointestinal side effects of current ...

Google News